ASH 2020
American Society of Hematology Annual Meeting
December 5-7, 2020 |
Virtual
Off-the-shelf, allogeneic SARS CoV-2 specific T-cells to treat high-risk patients with COVID-19
Therapeutic options for relapsed chronic lymphocytic leukemia after frontline chemoimmunotherapy
Efficacy and safety of asciminib in patients with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors
First data from the phase 3 HOPE-B gene therapy trial: Efficacy and safety of etranacogene dezaparvovec in adults with severe or moderate-severe Hemophilia B
Ruxolitinib versus best available therapy in patients with steroid-refractory/dependent chronic graft-versus-host disease: Primary findings from the phase 3, randomized REACH3 study
APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Updated Guidelines for the Management of Venous Thromboembolism (VTE)